Overview

The Gene Technology Act 2000 was enacted to regulate the handling, storage, and release of genetically modified organisms (GMOs) in Australia, addressing the need to balance the benefits of biotechnology with potential risks to human health and the environment. The Act was established by the Commonwealth Parliament with a policy objective to provide a robust regulatory framework that ensures the safe use of GMOs while facilitating innovation and economic growth. One of the Act's key provisions includes the requirement for a Risk Assessment and Risk Management Plan (RARMP) for applications involving the use of GMOs, which was developed by the Gene Technology Regulator in response to the application from the University of Tasmania to trial a genetically modified vaccine aimed at combating devil facial tumour disease in Tasmanian devils. This trial, if approved, would take place under controlled conditions in Tasmania, underscoring the Act's focus on protecting both human health and the environment while encouraging scientific research.

Scope and Application

The legislation, C2023G00385, pertains to a proposal by the University of Tasmania to trial a genetically modified (GM) vaccine designed to combat devil facial tumour disease in Tasmanian devils under strictly controlled conditions. This Act applies specifically to the entities involved in the application process, namely the Gene Technology Regulator and the University of Tasmania, as well as the conduct and transactions related to the trial of the GM vaccine within Tasmanian enclosures. The geographic scope of this Act is national, with the Regulator overseeing the application process under the purview of the Commonwealth. The Act does not explicitly mention any exclusions, exemptions, or thresholds but does note that a Risk Assessment and Risk Management Plan (RARMP) has been prepared to evaluate the potential risks to human health and safety and the environment. The Regulator is inviting submissions on the RARMP, with a submission deadline of 12 May 2023. The application process may be extended or restricted through subordinate instruments, which are not detailed in this particular Act.

Key Provisions

The main operative sections of the legislation (C2023G00385) pertain to the assessment and regulation of an application by the University of Tasmania for a trial of a genetically modified vaccine against devil facial tumour disease in Tasmanian devils (sections 1-3). Specifically, the Gene Technology Regulator is tasked with assessing the application and preparing a Risk Assessment and Risk Management Plan (RARMP) (section 2). The Regulator invites written submissions on the trial, focusing on the protection of human health, safety, and the environment (section 3). The consultation period for these submissions is until 12 May 2023, with all correspondence referencing DIR 195 (section 4). The obligations imposed by the Act primarily concern the Gene Technology Regulator. They must assess the application for the trial of the genetically modified vaccine, prepare the RARMP, and consider any written submissions received by the specified deadline (sections 2-4). Furthermore, the Regulator is required to make a decision on whether to issue the licence based on the assessment and any relevant submissions (section 5). The Act also requires the Regulator to provide the RARMP and related information to the public, accessible via their website or through direct contact (section 6). In terms of offences, penalties, or consequences for breach, the Act does not explicitly state any criminal or civil penalties for non-compliance with its provisions (sections 7-9). However, failure to adhere to the requirements of the Act, such as not submitting written submissions by the deadline or not considering them in the decision-making process, may result in legal challenges or administrative consequences. Additionally, if the trial were to proceed without proper assessment or approval, it could lead to legal action for unauthorised gene technology activities, with potential penalties including fines and imprisonment. The maximum penalties for unauthorised gene technology activities are not specified within the Act itself but are outlined in the Gene Technology Act 2000, which could include fines of up to $66,000 for individuals and $330,000 for corporations, as well as imprisonment for up to five years.